Katie Simon
Physician Assistant · Royal Oak, MINPI 1790204592
Payments from drug & device makers
Across 137 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$496
- Braeburn Inc.$209
- GSK$164
- Indivior Inc.$147
- Orexo US, Inc.$142
- Lilly USA, LLC$141
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,475100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $496 |
| Braeburn Inc. | 7 | $209 |
| GSK | 10 | $164 |
| Indivior Inc. | 9 | $147 |
| Orexo US, Inc. | 8 | $142 |
| Lilly USA, LLC | 7 | $141 |
| Otsuka America Pharmaceutical, Inc. | 8 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $135 |
| USWM, LLC | 2 | $80 |
| Pfizer | 4 | $74 |
| Lundbeck LLC | 3 | $72 |
| Axsome Therapeutics, Inc. | 3 | $68 |
| Amgen | 4 | $67 |
| Alkermes, Inc. | 4 | $66 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $65 |
| Merck | 4 | $53 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| Eisai Inc. | 2 | $40 |
| Phadia US Inc. | 2 | $34 |
| Paratek Pharmaceuticals, Inc. | 2 | $33 |
| Boehringer Ingelheim | 2 | $32 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| Johnson & Johnson | 1 | $28 |
| Bardy Diagnostics, Inc. | 2 | $28 |
| AstraZeneca | 2 | $27 |
| Novo Nordisk | 2 | $25 |
| Astellas Pharma US Inc | 1 | $18 |
| Ardelyx, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRIXADI$125
How this compares
$2,475 in reported general payments places this provider in the 85th percentile of 5,453 physician assistant providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 484 | $42,771 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 82 | $33,918 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $11,835 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 28 | $9,327 |
| Naloxone Hcl | 20 | $1,330 |
| Lactulose | 14 | $219 |
| Citalopram HbrCitalopram Hydrobromide | 15 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Orexo US, Inc.Zubsolv | $142 | $33,91882 claims |
| Axsome Therapeutics, Inc.Auvelity | $68 | $11,83511 claims |
| Indivior Inc.Suboxone | $147 | $9,32728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Royal Oak
- Sarang PatelRoyal Oak$660K
- Gabrielle DamoreRoyal Oak$200K
- Laura KingRoyal Oak$63K
- Inge HanschuRoyal Oak$21K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Taylor HennrickAdrian$430K
- Erin van DykeGrand Rapids$346K
- Ashley AldridgeAnn Arbor$298K
- Derek SusallaRochester Hills$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.